Results of an Australian trial of an automated insulin delivery (AID) system and other studies support likely benefit of AID use for many Australian adults with type 1 diabetes
Alicia J. Jenkins, Andrzej S. Januszewski, Adrienne Kirby, Christel Hendrieckx, Sybil A. McAuley, Melissa H. Lee, Barbora Paldus, Sara Vogrin, Martin I. de Bock, Mary B. Abraham, Leon A. Bach, Morton G. Burt, Neale D. Cohen, Peter G. Colman, Elizabeth A. Davis, D. J. Holmes-Walker, Joey Kaye, Anthony C. Keech, Kavita Kumareswaran, Richard J. MacIsaac, Roland W. McCallum, Catriona M. Sims, Jane Speight, Stephen N. Stranks, Vijaya Sundararajan, Steven Trawley, Glenn M. Ward, Timothy W. Jones, David N. O'Neal, for the Australian JDRF Closed Loop Research Group
{"title":"Results of an Australian trial of an automated insulin delivery (AID) system and other studies support likely benefit of AID use for many Australian adults with type 1 diabetes","authors":"Alicia J. Jenkins, Andrzej S. Januszewski, Adrienne Kirby, Christel Hendrieckx, Sybil A. McAuley, Melissa H. Lee, Barbora Paldus, Sara Vogrin, Martin I. de Bock, Mary B. Abraham, Leon A. Bach, Morton G. Burt, Neale D. Cohen, Peter G. Colman, Elizabeth A. Davis, D. J. Holmes-Walker, Joey Kaye, Anthony C. Keech, Kavita Kumareswaran, Richard J. MacIsaac, Roland W. McCallum, Catriona M. Sims, Jane Speight, Stephen N. Stranks, Vijaya Sundararajan, Steven Trawley, Glenn M. Ward, Timothy W. Jones, David N. O'Neal, for the Australian JDRF Closed Loop Research Group","doi":"10.1111/imj.16567","DOIUrl":null,"url":null,"abstract":"<p>Less than 20% of Australians with type 1 diabetes (T1D) meet recommended glucose targets. Technology use is associated with better glycaemia, with the most advanced being automated insulin delivery (AID) systems, which are now recommended as gold-standard T1D care. Our Australian AID trial shows a wide spectrum of adults with T1D can achieve recommended targets. Other studies, including lived experience data, are supportive. Insulin pumps are not subsidised for most Australian adults with T1D. We advocate change.</p>","PeriodicalId":13625,"journal":{"name":"Internal Medicine Journal","volume":"55 1","pages":"148-153"},"PeriodicalIF":1.8000,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Internal Medicine Journal","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/imj.16567","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Less than 20% of Australians with type 1 diabetes (T1D) meet recommended glucose targets. Technology use is associated with better glycaemia, with the most advanced being automated insulin delivery (AID) systems, which are now recommended as gold-standard T1D care. Our Australian AID trial shows a wide spectrum of adults with T1D can achieve recommended targets. Other studies, including lived experience data, are supportive. Insulin pumps are not subsidised for most Australian adults with T1D. We advocate change.
期刊介绍:
The Internal Medicine Journal is the official journal of the Adult Medicine Division of The Royal Australasian College of Physicians (RACP). Its purpose is to publish high-quality internationally competitive peer-reviewed original medical research, both laboratory and clinical, relating to the study and research of human disease. Papers will be considered from all areas of medical practice and science. The Journal also has a major role in continuing medical education and publishes review articles relevant to physician education.